Changing the World, One Molecule at a Time Dr. William P Purcell Chairman and Founder Jennifer Williams VP, Marketing 111 South Highland Street Memphis,

Slides:



Advertisements
Similar presentations
Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.
Advertisements

The Drug Discovery Process
Complexities of Designing a Research Exemption Arti K. Rai Professor, Duke Law School.
PIPELINE INFORMATION. Our mission is simple: make pharmaceutical information technology an asset for your business not a problem. We gather, analyze and.
Intellectual Property Rights, Investment and Transfer of Technology in the Pharmaceutical Sector Patrizia Carlevaro Head of the International Aid Unit.
Gilead’s Tech Transfer Partnerships and IP in India
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Technology Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. ( Vice President for Affiliate Members Association.
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders.
Do You Want to Start a Company? or Lessons from Babs’s Excellent Adventure Babs Soller, PhD Founder, President & Chief Scientific Officer Reflectance Medical.
Pharmaceutical Company Tracking Project TITAN PHARMACEUTICALS Samah Al-Shatnawi PCA-PhD student Mark 8660.
Technology and Economic Development Intellectual Property Issues in Research Jim Baker Director Office of Technology and Economic Development
IP Issues in Research Jim Baker, Executive Director Innovation, and Industry Engagement.
To List or Not to List? A Study of the Capital Careers of Acrux and Mesoblast David Blake – Co-editor, Bioshares University of Auckland Bioscience.
Skin Care and Science in Harmony Concert has discovered a novel dermatological ingredient, MDI 101, that improves the health of the skin. This discovery.
Ortec International, Inc. Developing Innovative Products To Advance Regenerative Medicine.
Surgery On Sunday Terri Cline, CSW, MSW Client Coordinator.
Adding Quality To Lives Utilizing Natures Healing Touch.
Forum On Financing Biotechs: Partnering The Biotech Perspective May 15, 2002 Celia Courchene VP, Business Development Xenon Genetics Inc. The Biotech Perspective.
... Accelerating Health PhiloMetron Inc. 1 FCC Spectrum and Mobile Applications Field Hearing 8 October 2009 Presented by: Darrel Drinan – CEO PhiloMetron.
Regulatory and Industry Requirements for Botanical Drug Products Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University.
National Institutes of Health Office of Extramural Research Matthew Portnoy, Ph.D. SBIR/STTR Program Manager Office of Extramural Research, NIH Commercialization.
Introduction Opportunity Market potential of recombinant drugs Problem Lack of manufacturing capacity Solution PharmOut: Contract BioManufacturing.
TRANSLATIONAL RESEARCH New Therapies for MS Dennis Bourdette, M.D. and Arthur A. Vandenbark, Ph.D. TCR peptide therapy Recombinant TCR ligand (RTL) therapy.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
National University of Singapore Department of Pharmacy 21 Nov 2006 KPP Prasad, Ph.D. Quality Operations Director Pfizer Global Manufacturing The Pharmaceutical.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Innovative Technology Transfer: Supporting a Strategic Delay Robert C. Bast, Jr., M.D. Vice President for Translational Research University of Texas M.D.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
15.4 Ethics and Impacts of Biotechnology
ZSX Medical Financing Questions Given the “total” amount of money ZSX needs to reach FDA clearance, are they best served by: 1.Seeking the money as proposed.
Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February
“Paying for clinical trials with an SBIR grant” Our experience obtaining millions of dollars through the NIH's Phase II Competing Renewal program Adapted.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
Bridging Gap in Global Innovation – From need to Access, Said Business School, University of Oxford 9-13 September 2007 Strategies for Managing Innovation.
FDA’s Role in Encouraging Innovation in Combination Products Danelle R. Miller, Esq. Regulatory Counsel, Roche Diagnostics For The Combination Products.
I n t e g r i t y - S e r v i c e - E x c e l l e n c e Headquarters U.S. Air Force Small Business Innovation Research (SBIR) Brief Dr. Sirie Blankenship.
CFO Track John Lawson & Pierre Bourassa Traditional Drug Development process.
1Managed by UT-Battelle for the U.S. Department of Energy ITS America May 2010 Technology Transfer Follows Many Pathways: “It’s a Contact Sport” Work for.
ADAMS & ADAMS Intellectual Property within the Pharmaceutical Industry Presentation to SAPRAA. 04 September 2009 By : Alexis Apostolidis B.Sc (Chem, Law);
China Healthcare Consulting Inc. Creating Value for Our Clients Boston Healthcare Associates, Inc. 75 Federal Street, 9 th Floor.
Developing medicines for the future and why it is challenging Angela Milne.
Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ +1.
New Technologies: the Role of the Private Sector Biotech’s Perspectives on Vaccine Development Alliances Peter Young CEO, AlphaVax, Inc.
Commercialization Plan Product Development Business model Financial plan BUSINESS PLAN Development strategy Budgets IDEA Invention Preface Fig 1.
VOLT01 Reformulated Zoledronic Acid Targeted to be the first Disease- Modifying Drug in Osteoarthritis.
Presentation by Dr. Andreas O. Tobler September 1, 2011 Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.
IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
Difference to Generics What can they do for us in the future
A Clinical Stage Drug Company Developing Polymolecular Therapeutics For The Oncology, Neurology And Orthopedic Markets Dr. Brent Reynolds, CEO
A Clinical Stage Drug Company Developing Polymolecular Therapeutics For The Oncology, Neurology And Orthopedic Markets Dr. Brent Reynolds, CEO
Venture Capital and the Finance of Innovation [Course number]
Biotechnology Chemical Pharmaceutical Customer Partnership
Technology Commercialization & Industry Partnering
Gestora brasileiro focada exclusivamente na área da saúde.
Partnering with Business and Industry
Distance Clinical Research Course & Its Importance
Finding and Understanding Patents
SBIR/STTR Program Award Structure SBIR/STTR Program Award Structure
Private sector involvement IPM-Tibotec case study
The Different Phases Of Clinical Trials
Jonathan Pirkl, VP of Business Development
Tamar Raz, PHD.
Areas of Potential Disputes
Finding and Understanding Patents
Pharmaceuticals Industry
Biocom CRO Presents: Concept to Commercial: A Clinical and Regulatory Outlook October 11, 2017.
Presentation transcript:

Changing the World, One Molecule at a Time Dr. William P Purcell Chairman and Founder Jennifer Williams VP, Marketing 111 South Highland Street Memphis, TN (901) Molecular Design International

 MDI is an invention engine for human health care  Multiple commercialization spin-outs  6 successful commercialization deals  34 years profitable business operations  IND approval and regulatory expertise  Over 10 Phase I & Phase II SBIR/STTR NIH ~ ($ 6Mil) All Phase II moved to Private Sector Phase III  Priority commercial focus: Safe and effective products for dermatology Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

1. All Natural Botanical Combination 2. Anti-Aging Serum 3. Wound Dressing 4. SensiClear Anti-Acne FOCUS MDI Proprietary Compounds, Ingredients, and Products Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

Proprietary All-Natural Botanical Combination Option to License from The University of Michigan Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

 Marketed non-exclusively at CVS Pharmacy under Dr. Dover’s Skin Effects, Intense Smoothing Serum with Retinoid Complex  Ingredients and formulation proprietary to MDI and Young Pharmaceuticals  This formulation or modifications thereof are available MDI 403 SERUM Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

 FDA Registration General and Plastic Surgery, number  MDI has the US marketing rights. Wound Dressing Patented Bacterial Biocellulose Film Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

SensiClear  Owned exclusively by MDI  Marketed through the Internet  Seek partner with strong marketing expertise Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

Miracle Worker by Philosophy MDI has an exclusivity Agreement with Philosophy/Coty for the ingredient, MDI 101. Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111

Molecular Design International, Inc. 111 South Highland Street, Suite 159 Memphis, TN 38111